Nektar Therapeutics, a clinical-stage biotechnology company specializing in immunotherapy, has successfully closed a public offering, raising $115 million. The company sold 4,893,618 shares of its common stock, which includes an additional 638,298 shares sold following the full exercise of the underwriters' option to purchase extra shares. The shares were sold at a price of $23.50 each. The proceeds from this offering will be used for general corporate purposes, including research, clinical development, and manufacturing costs to advance Nektar's drug candidates. Jefferies and Piper Sandler served as joint bookrunning managers for the offering, with BTIG, LLC and H.C. Wainwright & Co. also participating in management roles.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。